ISRAEL’S MEDICAL ACHIEVEMENTS
New target for cancer treatments. Researchers at Israel’s Bar Ilan University have discovered a new enzyme called FerT, which exists only in the energy-generating mitochondria of cancer cells. When the enzyme was targeted in lab tests, the malignant cells were unable to produce energy and died.
http://www.jewishpress.com/news/on-campus/israeli-scientists-discover-new-enzyme-to-destroy-in-metatastic-cancer-cells/2017/10/24/
US approval for Leukemia treatment. Following a Priority Review, the US FDA has approved Israel TEVA’s Leukemia treatment, TRISENOX® (arsenic trioxidec). Trisenox is to be used in combination with tretinoin for treatment of recently-diagnosed low-risk adults with acute promyelocytic leukemia (APL).
http://www.jewishpress.com/news/us-news/fda-approves-teva-leukemia-treatment/2018/01/15/
Lymphoma treatment approved. I reported previously (3rd Sep) on the US takeover of Israeli biotech Kite for $12 billion. The US FDA has now approved Kite’s Yescarta treatment for adults with relapsed or refractory large B-cell lymphoma. The treatment uses Israeli-developed CAR-T therapy from the patient’s own T-cells.
http://www.jns.org/news-briefs/2017/10/20/israeli-developed-breakthrough-cancer-drug-receives-fda-approval
Stem cell treatment inhibits cancer. I’ve reported previously (18 times) on Israeli biotech Pluristem’s PLX stem cell treatment for many life-threatening conditions. Recent lab trials with modified PLX cells showed significant inhibitory effect on various lines of breast, colorectal, kidney, liver, lung, muscle and skin cancers.
http://www.pluristem.com/wp-content/uploads/2018/01/PLX_Cancer_Publication_final_isa.pdf
https://www.nature.com/articles/s41598-017-18428-1
Successful trials of implant to prevent OAB. (TY Atid-EDI) I reported previously (July 2016) that the minimally invasive RENOVA leg implant from Israel’s BlueWind to treat Overactive Bladder (OAB) had been granted European approval. Recent trials show that device gave over 50% improvement to 71% of participants.
https://www.prnewswire.com/news-releases/bluewind-medical-announces-the-publication-of-breakthrough-results-for-bluewind-renova-implantable-tibial-nerve-neuromodulator-668016233.html
http://www.bluewindmedical.com/products